title: Efficacy and Safety of Loading-Dose Rosuvastatin Therapy in Elderly Patients with Acute Coronary Syndromes Undergoing Elective Percutaneous Coronary Intervention.
abstract: The aim of this work was to investigate the efficacy and safety of loading-dose rosuvastatin therapy in elderly patients with non-ST-segment elevation acute coronary syndromes (NSTEACS) undergoing elective percutaneous coronary intervention (PCI).
  
  
  
  A total of 126 patients (≥70 years old) with NSTEACS were randomly divided into two groups: (1) loading-dose rosuvastatin-treated group, treated with rosuvastatin 20 mg 12 h prior to PCI, with a second dose administered just before PCI (n = 62), and (2) control-treated group, treated with the standard method according to ACC/AHA guidelines in UAP/NSTEMI 2007 (n = 64). All patients were required to take rosuvastatin 10 mg once a day starting 24 h after the surgery irrespective of the initial randomization assignment. The serum soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLox-1), high-sensitivity C-reactive protein (hs-CRP), creatinine kinase (CK)-MB, cardiac troponin I (cTnI), and brain natriuretic peptide (BNP) levels were measured prior to PCI and at 24 h and 30 days after PCI in both groups. The left ventricular ejection fraction (LVEF) levels were recorded prior to PCI and 30 days after PCI in both groups.
  
  
  
  Compared to pre-PCI, the serum sLox-1, hs-CRP, CK-MB, and cTnI levels were increased at 24 h after PCI (all p < 0.05) in both groups. However, the increased sLox-1, hs-CRP, CK-MB, and cTnI values were significantly lower in the loading-dose rosuvastatin-treated group than in the control-treated group (p < 0.05). In addition the serum sLox-1 and hs-CRP levels were lower in the loading-dose rosuvastatin-treated group than in the control-treated group at 30 days after PCI. However, the decreased values of sLox-1and hs-CRP from 24 h after PCI to 30 days after PCI did not show any significant difference between the two groups. No significant difference was found in the serum ALT and Scr levels between the two groups before and after PCI. Compared to the control-treated group, the serum BNP level decreased (p < 0.05) and LVEF (p < 0.05) increased in the loading-dose rosuvastatin-treated group at 30 days after PCI.
  
  
  
  The loading-dose rosuvastatin therapy in elderly patients with non-ST-segment elevation acute coronary syndromes undergoing elective PCI can attenuate the increase in serum hs-CRP, sLox-1, CK-MB, and cTnI levels, reduce myocardial injury and inflammatory reaction caused by PCI, and improve the LVEF level at 30 days after PCI, ensuring an effective and safe therapy.
authors.affiliation: Department of Cardiology, Institute of Cardiovascular Disease, Zhongda Hospital of Southeast University Medical School, Southeast University, Nanjing, 210000, China.|Department of Cardiology, First People's Hospital of Yangzhou, The Second Clinical Medical School of Yangzhou University, Yangzhou, 225400, China.
authors.forename: Yungen
authors.initials: Y
authors.lastname: Jiao
authors.affiliation: Department of Cardiology, First People's Hospital of Yangzhou, The Second Clinical Medical School of Yangzhou University, Yangzhou, 225400, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Hu
authors.affiliation: Department of Cardiology, First People's Hospital of Yangzhou, The Second Clinical Medical School of Yangzhou University, Yangzhou, 225400, China.
authors.forename: Zhengang
authors.initials: Z
authors.lastname: Zhang
authors.affiliation: Department of Cardiology, First People's Hospital of Yangzhou, The Second Clinical Medical School of Yangzhou University, Yangzhou, 225400, China.
authors.forename: Kaizheng
authors.initials: K
authors.lastname: Gong
authors.affiliation: Department of Cardiology, First People's Hospital of Yangzhou, The Second Clinical Medical School of Yangzhou University, Yangzhou, 225400, China.
authors.forename: Xiaoning
authors.initials: X
authors.lastname: Sun
authors.affiliation: Department of Cardiology, First People's Hospital of Yangzhou, The Second Clinical Medical School of Yangzhou University, Yangzhou, 225400, China.
authors.forename: Aihua
authors.initials: A
authors.lastname: Li
authors.affiliation: Department of Cardiology, Institute of Cardiovascular Disease, Zhongda Hospital of Southeast University Medical School, Southeast University, Nanjing, 210000, China. liunf6666@163.com.
authors.forename: Naifeng
authors.initials: N
authors.lastname: Liu
mesh_terms: D054058:Acute Coronary Syndrome / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery*; D000368:Aged; D000369:Aged, 80 and over; D017558:Elective Surgical Procedures / Q000379:methods; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced / Q000175:diagnosis; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention / Q000379:methods; D000068718:Rosuvastatin Calcium / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000068718:Rosuvastatin Calcium